Insulin lispro (Humalog), the first marketed insulin analogue: Indications, contraindications and need for further study

CMAJ. Canadian Medical Association Journal

Volumn 158, Issue 4, 1998, Pages 506-511

  Puttagunta, Anuradha L ^a   Toth, Ellen L ^a,b,c  

^a Division of Endocrinology

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG TOLERABILITY; EXERCISE; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN PUMP; INSULIN RELEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PATIENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTPRANDIAL STATE; SELF INJECTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032562156     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Galloway JA, Chance RE. Insulin agonist therapy: a challenge for the 1990s. Clin Ther 1990;12(6):460-72.
2. Johnson IS. Authenticity and purity of human insulin (recombinant DNA). Diabetes Care 1982;5(suppl 2):4-12.
3. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
4. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54.
5. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7:188-99.
6. Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ. Algorithms for adjustments of insulin dosage by patients who monitor blood glucose. Diabetes Care 1981;4:311-8.
7. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
8. Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47-51.
9. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenno A, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994;37:713-20.
10. TerBraak EWM, Woodworth JR, Bianchi R. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996;19:1437-40.
11. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995;58:459-69.
12. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997;46:265-70.
13. Trautmann ME, Artanasio A, Schulze-Schleppinghoff B, Stiller R, Neiderreiter B, Haslbeck M, et al. Blood sugar control during treatment with an insulin analog [abstract]. Diabetologia 1993;36(suppl A):155.
14. Martin JM, Anderson DM. A short-acting insulin analogue in clinical practice [abstract]. Diabet Med 1994;11(suppl 11):S35.
15. Vignati L, Anderson J, Brunelle R. Efficacy of [Lys(B28), Pro(B29)] human insulin in a one year global randomized clinical trial [abstract]. Diabetes 1994;43(suppl 1):78A.
16. Vignati L, Anderson JH, Brunelle RL, Jefferson FL, Richardson M. Improvement of glycemic control with the rapidly absorbed lispro insulin analog in type I diabetes [abstract]. Diabetologia 1994;37(suppl 1):A78.
17. Anderson JH, Vignati L, Brunelle RL, Boggs B. Therapy of type II diabetes with insulin lispro, a rapidly absorbed insulin analog [abstract]. Diabetologia 1994;37(suppl 1):A169.
18. Brunelle RL, Anderson JH, Vignati L. Insulin lispro improves postprandial control in a large crossover study in patients with type II diabetes [abstract]. Diabetologia 1995;38(suppl 1):A3.
19. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Premeal insulin analogue insulin lispro vs Humulin insulin treatment in young subjects with type I diabetes. Diabetic Med 1996;13:47-52.
20. Torlone E, Pampanelli S, Lalli C. Effects of short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996;19:945-52.
21. Schmitt H, Symanowski SM, Holleman F, Rees A, Rottiers R, Anderson JH. Comparison of pre-meal therapy with insulin lispro and regular insulin in patients with IDDM [abstract]. Diabetologia 1996;39(suppl 1):A221.
22. Rowe R, Anderson JH, Gale E. A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen [abstract]. Diabetes 1996;45(suppl 2):71A.
23. Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, et al. Intensive insulin therapy with insulin lispro in patients with type I diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol 1996;104(1):25-30.
24. Holleman F, Hoekstra JBL. Insulin lispro [review]. N Engl J Med 1997;337: 176-82.
25. Pampanelli S, Torlone E, Lalli C, Sindaco PD, Ciofetta M, Lepore M, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function. Diabetes Care 1995;18:1452-9.
26. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AAR, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996;13:625-9.
27. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack TR. Insulin lispro in CSII: results of a double-blind, cross-over study. Diabetes 1997;46:440-3.
28. Tuominen JA, Karonen SL, Melamies L, Bolli G, Koivisto VA. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995;38:106-11.
29. Desmet M, Rutters A, Schmitt H, Satter E. [Lys(B28), Pro(B29)] human insulin (LysPro): patients treated with LysPro vs human regular insulin - quality of life assessment (QOL) [abstract]. Diabetes 1994;43(suppl 1):167A.
30. Fineberg NS, Fineberg SE, Anderson JH, Birkitt MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys(B28), Pro(B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996;45:1750-4.
31. Markussen J, Havelund S, Kurtzhals P, Anderson AS, Halstrom J, Hasselager E, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996;39:281-8.